Manuel Hernandez-Abril, MD
Pulmonary Disease · Miami, FLNPI 1265420657
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 70 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by GSK at 59.0% of the total. Reporting peaked in 2019 at $427 and has fallen 74.8% since, to $108 in 2025. That places this record below the midpoint for pulmonary disease clinicians in FL, where the typical reported total is $2,936.
Across 70 payments — averaging $19.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$793
- AstraZeneca$148
- Bristol Myers Squibb$128
- Boehringer Ingelheim$92
- Sunovion Pharmaceuticals Inc.$43
- Genentech USA, Inc.$40
- plus $102 from 4 others
Across 61 payments — averaging $30,892 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.6M
- Braintree Laboratories, Inc.$145K
- Sanofi US Services Inc.$51K
- Chiesi USA, Inc.$38K
- GSK$11K
What the payments were for
- Food & beverage$1,345100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 48 | $793 |
| AstraZeneca | 8 | $148 |
| Bristol Myers Squibb | 1 | $128 |
| Boehringer Ingelheim | 4 | $92 |
| Sunovion Pharmaceuticals Inc. | 2 | $43 |
| Genentech USA, Inc. | 3 | $40 |
| Johnson & Johnson | 1 | $27 |
| Philips North America LLC | 1 | $27 |
| Insmed, Inc. | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Abraxane$128
How this compares
$1,345 in reported general payments places this provider in the 35th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 876 | $579,570 |
| OfevNintedanib Esylate | 13 | $166,716 |
| Atrovent HfaIpratropium Bromide | 58 | $28,233 |
| Azelastine Hcl | 823 | $21,011 |
| Pirfenidone | 17 | $17,997 |
| Fluticasone Propionate | 1,340 | $15,979 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $14,267 |
| Montelukast Sodium | 1,031 | $4,657 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $3,752 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $3,552 |
| Budesonide | 22 | $3,478 |
| Varenicline Tartrate | 12 | $2,617 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 15 | $2,364 |
| Metoprolol Succinate | 128 | $1,319 |
| Bumetanide | 95 | $1,158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $793 | $579,570876 claims |
| Boehringer IngelheimOfev | $92 | $166,71613 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $148 | $17,81936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Miami
- Javier Perez FernandezMiami$496K
- Raul ValorMiami$232K
- Shirin ShafazandMiami$193K
- Michael HernandezMiami$153K
- Ignacio CendanMiami$140K
- Andres SosaMiami$91K
- Jaime AvecillasMiami$70K
- Franck RahaghiWeston$1.2M
- Michael OttEglin Afb$909K
- Ali JiwaniOrlando$859K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.